606144-05-2 Usage
General Description
The chemical compound 5-(4-bromo-2-chlorophenylamino)-4-fluoro-1-methyl-N-(2-(vinyloxy)ethoxy)-1H-benzo[d]iMidazole-6-carboxamide is a complex molecule with multiple functional groups. It contains a benzimidazole core structure with a substituted amine, fluoro, bromo, and chloro groups attached to the benzene ring. Additionally, it has a methyl and carboxamide group attached to the benzimidazole core. The compound also features an ethoxy and vinyloxy group linked to the nitrogen at position 1 of the benzimidazole ring. This chemical structure suggests potential pharmaceutical applications, as benzimidazole derivatives have been investigated for their various pharmacological activities, such as antimicrobial, antiviral, antitumor, and anti-inflammatory properties.
Check Digit Verification of cas no
The CAS Registry Mumber 606144-05-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,0,6,1,4 and 4 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 606144-05:
(8*6)+(7*0)+(6*6)+(5*1)+(4*4)+(3*4)+(2*0)+(1*5)=122
122 % 10 = 2
So 606144-05-2 is a valid CAS Registry Number.
606144-05-2Relevant articles and documents
INTERMEDIATES OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MAP2K OR MEK) INHIBITORS AND PROCESS FOR THEIR PREPARATION
-
Page/Page column 11, (2018/04/21)
The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to process for the 5 preparation of MEK inhibitors such as Selumetinib, and Binimetinib.
N3 alkylated benzimidazole derivatives as MEK inhibitors
-
Page 10; 23, (2008/06/13)
Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.